Multiple 2026 post-hoc and real-world analyses (SURPASS-CVOT, PCI/TAVR cohorts) amplifying original trial; >1,000 social mentions in past 14 days, widespread news coverage linking to reduced CV risk post-procedure, high clinical buzz on GLP-1/GIP use in cardiology.
Tirzepatide reduced the risk of death from cardiovascular causes or worsening heart failure compared to placebo in patients with heart failure with preserved ejection fraction and obesity.
Does tirzepatide reduce the risk of cardiovascular death or worsening heart failure in patients with heart failure with preserved ejection fraction and obesity?
Patients with heart failure with preserved ejection fraction and obesity
Tirzepatide
Placebo
Composite of death from cardiovascular causes or worsening heart failurecomposite
Tirzepatide reduces the risk of cardiovascular death or worsening heart failure and improves health status in patients with HFpEF and obesity.
Treatment with tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure than placebo and improved health status in patients with heart failure with preserved ejection fraction and obesity. (Funded by Eli Lilly; SUMMIT ClinicalTrials.gov number, NCT04847557.).
“In my mind, this really is a practice-changing trial and cements incretin-based therapies as one of the cornerstones of obesity-HFpEF treatment.”
Building similarity graph...
Analyzing shared references across papers
Loading...
Milton Packer
Michael R. Zile
Christopher M. Kramer
New England Journal of Medicine
Medical University of South Carolina
Baylor University Medical Center
University of Virginia Health System
Building similarity graph...
Analyzing shared references across papers
Loading...
Packer et al. (Sat,) reported a other. Tirzepatide reduced the risk of death from cardiovascular causes or worsening heart failure compared to placebo in patients with heart failure with preserved ejection fraction and obesity.
www.synapsesocial.com/papers/6960145533e82041331c57f5 — DOI: https://doi.org/10.1056/nejmoa2410027